Susan Morrison - 25 May 2022 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Role
EVP & Chief Admin. Officer
Signature
/s/ Rachel Malina, Attorney-in-Fact for Susan M. Morrison
Issuer symbol
TNDM
Transactions as of
25 May 2022
Net transactions value
$0
Form type
4
Filing time
27 May 2022, 21:52:46 UTC
Previous filing
18 May 2022
Next filing
01 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TNDM Common Stock 9,376 25 May 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNDM Restricted Stock Unit Award $0 +5,691 $0.000000 5,691 25 May 2022 Common Stock 5,691 Direct F1, F2, F3
transaction TNDM Performance Stock Unit Award $0 +5,523 $0.000000 5,523 25 May 2022 Common Stock 5,523 Direct F1, F4
transaction TNDM Stock Option Award $0 +8,544 $0.000000 8,544 25 May 2022 Common Stock 8,544 $65.28 Direct F1, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Awarded on May 25, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").
F2 Each restricted stock unit ("RSU") represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the2013 Plan.
F3 RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on the 15th day of the month that corresponds to the anniversary of the grant date, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter, subject to the terms of the 2013 Plan.
F4 Each performance stock unit ("PSU") represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the "Company") common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the "Measurement Date"). The number of shares issued may range from 0% to 200 % of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSU's will vest.
F5 The option shall vest as to thirty-three percent (33%) of the underlying shares on the one-year anniversary of the grant date, and the remaining shares shall vest in twenty-four (24) equal monthly installments thereafter, subject to the terms of the 2013 Plan.
F6 The expiration date for these options is 10 years from the date of grant.